However, when considering individual adverse effect profiles, the differentiation into first- and second-generation antipsychotics as unified classes cannot be supported, and a more differentiated view and treatment selection is required. To date, clozapine is the only evidence-based treatment for refractory patients, and the role of antipsychotic polypharmacy and other augmentation strategies Selleckchem IBET151 remains unclear, at best. To improve the treatment outcomes in schizophrenia, research efforts are needed Inhibitors,research,lifescience,medical that elucidate biomarkers

of the illness and of treatment response (both therapeutic and adverse effects). Moreover, new treatment options are needed that affect nondopaminergic targets with relevance for symptom reduction Inhibitors,research,lifescience,medical in various domains, relapse prevention, enhanced efficacy for nonresponders, and reduced key adverse effects. Effective treatments for cognitive dysfunction and negative symptoms and those positively affecting functional outcomes are sorely needed. Furthermore, the combined use of pharmacologic and nonpharmacologic cognitive, behavioral, vocational, and psychosocial approaches needs to be studied more, and management strategies for lack of illness insight Inhibitors,research,lifescience,medical and adherence should be developed further. Acknowledgments Grant support: The Zucker

Hillside Hospital Advanced Center for Intervention and Services Research for the Study of Schizophrenia (MH074543-01) from the National Institute of Mental Health, Bethesda, Maryland. Disclosures: Dr Kane has been a consultant to Astra-Zeneca, Janssen, Pfizer,

Eli Lilly, Bristol-Myers Squibb, Otsuka, Vanda, Proteus, Takeda, Targacept, Inhibitors,research,lifescience,medical Intracellular Therapeutics, Rules Based Medicine , and has received honoraria for lectures from Otsuka, Eli Lilly, Bristol-Myers Squibb, and Janssen. Dr Correll has been a consultant and/or advisor to Actelion, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Inhibitors,research,lifescience,medical Janssen/J&J, GSK, Hoffmann-La Roche, Medicure, Otsuka, Pfizer, Schering-Plough, Supernus, Takeda, and Vanda.
Obsessive-compulsive next disorder (OCD) is a severe mental illness characterized by intrusive, repetitive, and bothersome thoughts (ie, obsessions) usually followed by ritualized behavior (ie, compulsions such as excessive hand-washing for fear of transmitting diseases) aimed at neutralizing the obsessive contents.1 As a consequence of OCD, the majority of patients are confronted with vast economic and social problems; many patients are unable to work, and lack a stable social network. Quality of life is usually very low,2,3 and comorbid depression is diagnosed in one to two thirds of all patients.3 Effective treatment strategies have been at hand for quite some time now.